Pseudolaric acid B-O-β-D-glucopyranoside is primarily studied for its potential therapeutic applications, particularly in the field of oncology. Research indicates that it exhibits significant anti-cancer properties, making it a candidate for the development of novel cancer treatments. It has been shown to inhibit the proliferation of various cancer cell lines, including those associated with breast, lung, and liver cancers. The compound works by inducing apoptosis, or programmed cell death, in malignant cells, thereby reducing tumor growth. Additionally, it has been observed to enhance the efficacy of conventional chemotherapy drugs, suggesting a role in combination therapies. Beyond oncology, there is emerging interest in its anti-inflammatory and immunomodulatory effects, which could be harnessed for treating autoimmune diseases and chronic inflammatory conditions. It also demonstrates antimicrobial activity, particularly antifungal properties, potentially useful for infectious diseases. Its ability to modulate key signaling pathways involved in cell survival and inflammation further underscores its potential as a multi-target therapeutic agent. Ongoing studies aim to explore its safety profile, pharmacokinetics, and potential for clinical application.